207 related articles for article (PubMed ID: 20483709)
1. [Focus on GIST management].
Tardieu M; Dômont J; Cioffi A; Bonvalot S; Le Cesne A
Bull Cancer; 2010 Jun; 97(6):723-31. PubMed ID: 20483709
[TBL] [Abstract][Full Text] [Related]
2. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Italiano A; Bui B
Bull Cancer; 2008 Jan; 95(1):107-16. PubMed ID: 18230576
[TBL] [Abstract][Full Text] [Related]
3. [KIT and KIT: from biology to clinical use].
Curtit E; Mansi L; Viel E; Dobi E; Chaigneau L; Nguyen T; Pivot X; Blay JY; Kalbacher E
Bull Cancer; 2012 Feb; 99(2):191-7. PubMed ID: 21669561
[TBL] [Abstract][Full Text] [Related]
4. Current and future management of GIST.
Blanke C
Clin Adv Hematol Oncol; 2006 Aug; 4(8):582-3. PubMed ID: 17099615
[No Abstract] [Full Text] [Related]
5. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
[TBL] [Abstract][Full Text] [Related]
6. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
Adenis A; Blay JY; Bui-Nguyen B; Bouché O; Bertucci F; Isambert N; Bompas E; Chaigneau L; Domont J; Ray-Coquard I; Blésius A; Van Tine BA; Bulusu VR; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Le Cesne A
Ann Oncol; 2014 Sep; 25(9):1762-1769. PubMed ID: 25122671
[TBL] [Abstract][Full Text] [Related]
7. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in therapy for gastrointestinal stromal tumors.
Maki RG
Curr Oncol Rep; 2007 May; 9(3):165-9. PubMed ID: 17430686
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
[TBL] [Abstract][Full Text] [Related]
10. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
Italiano A; Cioffi A; Coco P; Maki RG; Schöffski P; Rutkowski P; Le Cesne A; Duffaud F; Adenis A; Isambert N; Bompas E; Blay JY; Casali P; Keohan ML; Toulmonde M; Antonescu CR; Debiec-Rychter M; Coindre JM; Bui B
Ann Surg Oncol; 2012 May; 19(5):1551-9. PubMed ID: 22065192
[TBL] [Abstract][Full Text] [Related]
11. Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.
Apice G; Milano A; Bruni GS; Iaffaioli RV; Caponigro F
Rev Recent Clin Trials; 2006 Jan; 1(1):35-42. PubMed ID: 18393778
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib.
Svetlichnaya J; Huyck TK; Wayne JD; Agulnik M
Chemotherapy; 2012; 58(1):30-3. PubMed ID: 22415035
[TBL] [Abstract][Full Text] [Related]
13. Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?
von Mehren M; Watson JC
Oncology (Williston Park); 2009 Jan; 23(1):65-6. PubMed ID: 19283923
[No Abstract] [Full Text] [Related]
14. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
15. Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
Kim EJ; Zalupski MM
J Surg Oncol; 2011 Dec; 104(8):901-6. PubMed ID: 22069175
[TBL] [Abstract][Full Text] [Related]
16. Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
von Mehren M
Clin Colorectal Cancer; 2006 Nov; 6 Suppl 1():S30-4. PubMed ID: 17419150
[TBL] [Abstract][Full Text] [Related]
17. C-kit, GIST, and imatinib.
Siehl J; Thiel E
Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922
[TBL] [Abstract][Full Text] [Related]
18. [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
Thomas X
Bull Cancer; 2007 Oct; 94(10):871-80. PubMed ID: 17964981
[TBL] [Abstract][Full Text] [Related]
19. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
Nishida T; Omori T; Ueshima S
Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal stromal tumors: current management.
Pisters PW; Patel SR
J Surg Oncol; 2010 Oct; 102(5):530-8. PubMed ID: 20063363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
